Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 201 to 250 of 308

Type: GuidanceRemove Type: Guidance filter

Guidance and quality standards awaiting development
Title	Type
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]	Technology appraisal guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]	Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance
Pulsed Field Ablation (PFA) for atrial fibrillation	Interventional procedures guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130	Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549	Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642	Technology appraisal guidance
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443	Technology appraisal guidance
Remdesivir for treating COVID 19 [ID3808]	Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines TS ID 11903	Technology appraisal guidance
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer TS ID 11851	Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905	Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436	Technology appraisal guidance
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]	Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]	Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]	Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764	Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763	Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]	Technology appraisal guidance
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]	Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814	Technology appraisal guidance
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]	Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433	Technology appraisal guidance
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237	Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over TS ID 11846	Technology appraisal guidance
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]	Technology appraisal guidance
Selpercatinib for treating advanced thyroid cancer with RET alterations (MA review of TA742) [ID6288]	Technology appraisal guidance
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options TS ID 11850	Technology appraisal guidance
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441	Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis TS ID 11945	Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)	Technology appraisal guidance
Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]	Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995	Technology appraisal guidance
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827	Technology appraisal guidance
Single-step scaffold insertion for repairing symptomatic chondral knee defects	Interventional procedures guidance
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147	Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]	Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]	Technology appraisal guidance
Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions	Medical technologies guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]	Technology appraisal guidance
STS101 for treating acute migraine TS ID 11782	Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409	Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977	Technology appraisal guidance
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008	Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009	Technology appraisal guidance
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]	Technology appraisal guidance
Targeted Muscle Reinnervation for refractory pain after limb amputation	Interventional procedures guidance
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]	Technology appraisal guidance

Results per page

10
25
50
All